These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31713130)

  • 41. Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin.
    Loupa CV; Lykoudi E; Meimeti E; Moisoglou I; Voyatzoglou ED; Kalantzi S; Konsta E
    Med Arch; 2020 Jun; 74(3):243-245. PubMed ID: 32801445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
    Amara S; Adamson RT; Lew I; Huang X
    Curr Med Res Opin; 2013 Jul; 29(7):869-77. PubMed ID: 23659559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Examination of hospital length of stay in Canada among patients with acute bacterial skin and skin structure infection caused by methicillin-resistant Staphylococcus aureus.
    Potashman MH; Stokes M; Liu J; Lawrence R; Harris L
    Infect Drug Resist; 2016; 9():19-33. PubMed ID: 26869806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
    Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
    Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin.
    Volpicelli L; Venditti M; Oliva A
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):329-341. PubMed ID: 36803139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
    Oliva A; Carbonara S; Cianci V; Crapis M; Di Domenico EG; Falcone M; Galardo G; Durante-Mangoni E; Venditti M
    Expert Rev Anti Infect Ther; 2023; 21(7):703-721. PubMed ID: 37227028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
    Bassetti M; Labate L; Vena A; Giacobbe DR
    Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol.
    Durante-Mangoni E; Riccardi A; Guarino M; Cesaro F; Lugarà M; Mascolo S; Morelli L; Natale V; Andreoni M
    J Chemother; 2023 Sep; 35(5):397-403. PubMed ID: 36264157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.
    Claeys KC; Zasowski EJ; Trinh TD; Casapao AM; Pogue JM; Bhatia N; Mynatt RP; Wilson SS; Arthur C; Welch R; Sherwin R; Hafeez W; Levine DP; Kaye KS; Delgado G; Giuliano CA; Takla R; Rieck C; Johnson LB; Murray KP; Gordon J; Reyes K; Hartman P; Davis SL; Rybak MJ
    Infect Dis Ther; 2019 Jun; 8(2):199-208. PubMed ID: 30915685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
    Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
    Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
    Zinzi D; Vlachaki I; Falla E; Mantopoulos T; Nathwani D
    Eur J Health Econ; 2022 Nov; 23(8):1371-1381. PubMed ID: 35113269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
    Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
    Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.
    Talan DA; Mower WR; Lovecchio FA; Rothman RE; Steele MT; Keyloun K; Gillard P; Copp R; Moran GJ
    Acad Emerg Med; 2021 Oct; 28(10):1108-1117. PubMed ID: 33780567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States.
    Keyloun KR; Weber DJ; Gardstein BM; Berger A; Gillard P; Ganz ML
    Hosp Pract (1995); 2018 Dec; 46(5):278-286. PubMed ID: 30067108
    [No Abstract]   [Full Text] [Related]  

  • 58. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
    Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice.
    Hanses F; Dolff S; Trauth J; Seimetz M; Hagel S
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.